Skip to main content
EyeGene,Inc logo

EyeGene,Inc — Investor Relations & Filings

Ticker · 185490 ISIN · KR7185490000 KO Professional, scientific and technical activities
Open in API
Filings indexed 314 across all filing types
Latest filing 2026-05-15 Major Shareholding Noti…
Country KR South Korea
Listing KO 185490

About EyeGene,Inc

https://eyegene.co.kr/en/

EyeGene, Inc. is a clinical-stage biopharmaceutical company that researches and develops innovative therapeutics, with a primary focus on gene and cell therapy for age-related diseases. The company's pipeline includes EG-Mirotin, a treatment candidate for non-proliferative diabetic retinopathy and dry age-related macular degeneration. EyeGene is also developing preventive vaccines, such as EG-HPV for cervical cancer, utilizing its proprietary EG-Vac adjuvant system to enhance vaccine efficacy. The company is dedicated to creating transformative treatments by advancing biomedical science.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 85% confidence The document is a “주식등의 대량보유상황보고서” – a statutory large shareholding report by a major shareholder and its affiliates in a listed company. It details the number of shares held, changes over a specified period, acquisition methods, and beneficial ownership under Korean capital markets law. This is a notification of changes in significant share ownership levels, matching the Major Shareholding Notification category.
2026-05-15 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 88% confidence The document is titled “분기보고서” (Quarterly Report) for the period 2026-01-01 to 2026-03-31, filed with the Financial Services Commission and Korea Exchange. It contains detailed company overview, corporate structure, business segments, pipeline data, and is clearly a standalone quarterly financial report rather than an announcement or summary. Therefore it fits the definition of an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' which translates to 'Report on Large Shareholding Status'. It contains detailed information about shareholdings, changes in share ownership, and related disclosures for a company named 아이진 주식회사 (Eyegene Co., Ltd.). The document includes specifics such as the number of shares held, changes in shareholding percentages, dates of transactions, and the purpose of holding shares, which is related to management control. This type of document corresponds to notifications about major shareholding changes, typically required by securities regulations to disclose significant ownership stakes and changes therein. There is no indication that this is an annual report, earnings release, or any other type of financial or management report. It is a detailed disclosure of share ownership changes by major shareholders and related parties. Therefore, the appropriate classification is Major Shareholding Notification (Code: MRQ). The document length (9922 characters) and content confirm it is a full report, not just an announcement or certification.
2026-05-07 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled “정기주주총회결과” (Annual General Meeting results) and lists each AGM resolution (approval of financial statements, board remuneration caps, option grants) with vote outcomes (approval status, percentages). It provides official voting results from the shareholder meeting, matching the “Declaration of Voting Results & Voting Rights Announcements” definition (Code DVA).
2026-03-31 Korean
사업보고서 (2025.12)
Interim / Quarterly Report Classification · 95% confidence The document is a comprehensive 'Consolidated Audit Report' (연결감사보고서) for EyeGene Inc. (아이진 주식회사) for the fiscal year ending December 31, 2025. It includes the independent auditor's report, consolidated financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. This constitutes a full annual financial report for a period shorter than a full fiscal year in terms of the reporting cycle, but it is the primary annual financial disclosure. Given the definition provided, this document is classified as an Interim/Quarterly Report (IR) because it contains the full set of audited financial statements and substantive financial analysis for the reporting period, distinguishing it from a simple earnings release or a summary. FY 2025
2026-03-19 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by the company '아이진'. It contains detailed financial tables including consolidated and separate financial statements, audit opinions, and key financial metrics for the fiscal year. While it provides financial data, it is a regulatory filing specifically announcing the submission of the audit report to the exchange, which is a standard requirement in the Korean market (DART system). Given the structure and content, it falls under the category of Audit Report / Information. FY 2025
2026-03-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.